Showing results (131-140 of 144) with videos related to
Sort By:
Pageof 15
Circulation|June 5, 2003
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathyMichael Arad, Ivan P Moskowitz, Vickas V Patel, et al.Journal of the American College of Cardiology|August 27, 2025
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM TrialMilind Y Desai, Iacopo Olivotto, Theodore Abraham, et al.Molecular Genetics and Metabolism|July 19, 2018
European expert consensus statement on therapeutic goals in Fabry diseaseChristoph Wanner, Michael Arad, Ralf Baron, et al.ESC Heart Failure|February 19, 2026
Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathyCaroline J Coats, Theodore Abraham, Roberto Barriales-Villa, et al.European Heart Journal|April 7, 2021
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial DiseasesPablo Garcia-Pavia, Claudio Rapezzi, Yehuda Adler, et al.European Journal of Heart Failure|April 7, 2021
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesPablo Garcia-Pavia, Claudio Rapezzi, Yehuda Adler, et al.JACC. Heart Failure|November 30, 2023
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study DesignCaroline J Coats, Martin S Maron, Theodore P Abraham, et al.The New England Journal of Medicine|May 13, 2024
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Michael E Nassif, et al.Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.Journal of the American College of Cardiology|October 1, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMMartin S Maron, Ahmad Masri, Michael E Nassif, et al.Pageof 15